Priority Research Papers:
MDM2 antagonists synergize broadly and robustly with compounds targeting fundamental oncogenic signaling pathways
Metrics: PDF 2168 views | HTML 2660 views | ?
Anne Y. Saiki1,*, Sean Caenepeel1,*, Dongyin Yu1, Julie A. Lofgren1, Tao Osgood1, Rebecca Robertson1, Jude Canon1, Cheng Su2, Adrie Jones3, Xiaoning Zhao3, Chetan Deshpande4, Marc Payton1, Jebediah Ledell5, Paul E. Hughes1 and Jonathan D. Oliner1
1 Department of Oncology Research, Amgen, Thousand Oaks, CA
2 Department of Biostatistics, Amgen, Seattle, WA
3 Department of Molecular Structure and Characterization, Amgen, South San Francisco, CA
4 Department of Molecular Sciences and Computational Biology, Amgen, Thousand Oaks, CA
5 Department of Biology, Zalicus, Cambridge, MA
* Equal contribution
Jonathan D. Oliner, email:
Keywords: MDM2, synergy, MEK, MAPK, PI3K, FOXM1
Received: April 2, 2014 Accepted: April 22, 2014 Published: April 23, 2014
While MDM2 inhibitors hold great promise as cancer therapeutics, drug resistance will likely limit their efficacy as single agents. To identify drug combinations that might circumvent resistance, we screened for agents that could synergize with MDM2 inhibition in the suppression of cell viability. We observed broad and robust synergy when combining MDM2 antagonists with either MEK or PI3K inhibitors. Synergy was not limited to cell lines harboring MAPK or PI3K pathway mutations, nor did it depend on which node of the PI3K axis was targeted. MDM2 inhibitors also synergized strongly with BH3 mimetics, BCR-ABL antagonists, and HDAC inhibitors. MDM2 inhibitor-mediated synergy with agents targeting these mechanisms was much more prevalent than previously appreciated, implying that clinical translation of these combinations could have far-reaching implications for public health. These findings highlight the importance of combinatorial drug targeting and provide a framework for the rational design of MDM2 inhibitor clinical trials.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.